US · USD
BMRN
Biomarin Pharmaceutical Inc
- Day's range
- $56.17 – $57.88
- Day's volume
- $18.7M
- 52-week range
- $49.67 – $70.24
Follow BMRN in the Fuolio
See how BMRN weighs in your net worth, what it has paid you and how far it is from your target allocation.
Create a free accountBMRN in numbers
- Market cap
- $11B
- P/E
- 150.93
- P/B
- 1.74
- Dividend yield (12m)
- 0.00%
- Net debt/EBITDA
- 10.96
BMRN trades at 150.93 times its earnings of the last 12 months.
BMRN price history
BMRN risk and return
Monthly closes adjusted for splits and distributions.
| Metric | 12 months | 36 months | 60 months |
|---|---|---|---|
| Return | +1.73% | -37.53% | -34.07% |
| Volatility (annualized) | 22.50% | 25.17% | 25.52% |
| Largest drawdown | -12.78% | -44.44% | -53.56% |
| Positive months | 5/12 | 15/36 | 28/60 |
How much did investing in BMRN return?
$1,000.00 invested on 11/01/2021 would be worth $659.35 today.
- Value today in BMRN
- $659.35
- Return over the period
- -34.07%
- Return per year
- -8.10%
- In the S&P 500
- $1,715.32
With dividends reinvested, before taxes and costs, at month-end closes. Past returns do not guarantee future ones.
BMRN fundamentals
Valuation
- P/E150.93
- P/B1.74
- EV/EBITDA47.23
- EV/EBIT95.63
- EV/Revenue4.19
- P/EBIT73.44
- P/S3.22
- P/OCF12.79
- P/FCF14.85
- Earnings yield1.05%
- PEG ratio—
- Earnings per share$0.38
- Book value per share$32.66
Debt
- Net debt$3.3B
- Net debt/EBITDA10.96
- Net debt/Equity0.52
- Debt/Equity0.66
- Current ratio2.39
- Quick ratio1.32
- Cash ratio0.53
Efficiency
- Gross margin76.12%
- EBITDA margin8.87%
- Operating margin4.38%
- Net margin2.14%
- Asset turnover0.29
Profitability
- ROE1.15%
- ROA0.62%
- ROIC0.76%
- Payout0.00%
Growth
- Revenue CAGR (5 years)12.19%
- Earnings CAGR (5 years)-38.54%
- Revenue growth (year)—
- Earnings growth (year)—
- Revenue growth (quarter)—
- Earnings growth (quarter)—
What is BMRN's fair price?
Two classic value formulas, with today's numbers. The current price is $56.90.
- Graham's fair price
- $16.64
- 70.75% below the price
√(22.50 × $0.38 × $32.66)
Benjamin Graham paid no more than a P/E of 15 and a P/B of 1.5. Their product, 22.5, times earnings (EPS) and book value per share gives the fair price.
- Bazin's ceiling price
- —
- Does not apply to BMRN: it paid no distributions in the last five years.
Décio Bazin only bought stocks yielding at least 6% a year in distributions. The ceiling price is the average dividend per share of recent years over 6%.
Graham ignores growth and debt; Bazin assumes past distributions repeat. They are references to compare, not a buy recommendation.
BMRN's indicators by year
Multiples at each year's closing price; margins and returns from that year's statements.
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| P/E | 32.76 | 29.37 | 108.54 | 136.33 | -253.65 | 18.67 | -637.90 | -196.71 |
| P/B | 1.88 | 2.22 | 3.67 | 4.19 | 3.81 | 3.89 | 4.87 | 5.12 |
| EV/EBITDA | 21.91 | 21.60 | 62.70 | 73.41 | 632.70 | 258.29 | 3,141.17 | — |
| Earnings per share | $1.81 | $2.24 | $0.89 | $0.76 | -$0.35 | $4.70 | -$0.13 | -$0.43 |
| Book value per share | $31.65 | $29.66 | $26.24 | $24.68 | $23.18 | $22.55 | $17.35 | $16.64 |
| ROE | 5.73% | 7.55% | 3.38% | 3.08% | -1.50% | 20.83% | -0.76% | -2.60% |
| ROIC | 5.51% | 6.74% | 3.34% | 3.31% | -1.64% | -0.00% | -0.81% | -2.25% |
| Gross margin | 77.73% | 79.67% | 78.01% | 76.00% | 74.52% | 71.82% | 78.91% | 78.86% |
| EBITDA margin | 15.18% | 20.35% | 11.99% | 12.54% | 1.39% | 3.32% | 0.28% | -1.87% |
| Net margin | 10.83% | 14.96% | 6.93% | 6.76% | -3.47% | 45.90% | -1.40% | -5.18% |
| Net debt/EBITDA | -1.46 | — | — | — | — | — | — | — |
BMRN's financial statements
| Line | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net revenue | $3.2B | $2.9B | $2.4B | $2.1B | $1.8B | $1.9B |
| Cost of revenue | -$717.4M | -$580.2M | -$532.1M | -$503M | -$470.5M | -$524.3M |
| Gross profit | $2.5B | $2.3B | $1.9B | $1.6B | $1.4B | $1.3B |
| EBITDA | $489M | $580.6M | $290.2M | $262.9M | $25.7M | $61.7M |
| EBIT | $409.5M | $484.2M | $185.8M | $161M | -$82.3M | -$43.4M |
| Financial result | — | — | — | — | — | — |
| Income before tax | $482.5M | $541.8M | $188.6M | $149.6M | -$75.4M | -$49M |
| Income tax | -$133.6M | -$114.9M | -$20.9M | -$8M | $11.3M | $903M |
| Net income | $348.9M | $426.9M | $167.6M | $141.6M | -$64.1M | $854M |
Figures the company filed with the CVM. Debt excludes leases; each quarter is that quarter alone.
Does BMRN pay dividends?
BMRN has no distributions on record.
About Biomarin Pharmaceutical
- Sector
- Manufacturing
Questions about BMRN
How much is BMRN today?
BMRN is at $56.90 (-1.12% on the day), last traded on 10/06/2026.
What are the P/E and P/B of BMRN?
BMRN trades at a P/E of 150.93 and a P/B of 1.74.
How much did BMRN return in 12 months?
BMRN returned 1.73% in 12 months, with annualized volatility of 22.50% and a largest drawdown of -12.78%.